Develop and register a solid, taste-masked, first line lopinavir/ritonavir-based fixed-dose formulation with two nucleoside reverse transcriptase inhibitors (NRTIs), lamivudine and abacavir
current phase of drug development
updated 14 Jun 2022
The objective of the 4-in-1 was to combine the four drugs needed for the treatment of paediatric HIV into a single, easy-to-use granule-filled capsule, also called a fixed-dose combination, which is heat-stable, taste-masked, solid, and does not contain alcohol or inappropriate solvents.
The ‘4-in-1’ fixed-dose combination combines the protease inhibitors lopinavir and ritonavir with the nucleoside reverse transcriptase inhibitors (NRTIs) lamivudine and abacavir.
Developed for infants and young children weighing from 3 to 25kg, parents and caregivers will be able to administer the drugs by opening the capsules and sprinkling the granules on soft food, water, or milk. The 4-in-1 does not require refrigeration and is a significant improvement over currently available lopinavir-based regimens.
News & resources
- 29 June 2022 - HIV child medicine that cut the ‘Yuck’ cleared in South Africa, Bloomberg
- 25 June 2022 - New ‘breakthrough’ treatment for infants with HIV, The Citizen
- 15 June 2022 - Cipla introduces HIV drug for children in South Africa that won’t need refrigeration, CNBC-TV18
- 15 June 2022 - New HIV treatment designed for young children gains first approval in South Africa, HealthCare Africa
- 14 June 2022 - Cipla and DNDi launch child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa
- 29 November 2019 - HIV treatment for children to be produced for under one dollar a day
- 17 June 2019 - First patient for “LOLIPOP” study for HIV treatment
- 4 June 2019 - Study for a child-friendly HIV treatment begins in Uganda
- 11 December 2012 - Grant from UNITAID awarded to bolster development and delivery of child-adapted antiretroviral (ARV) formulation
- 19 July 2012 - DNDi and Cipla to Develop 4-in-1 Paediatric Antiretroviral Drug Combination – New formulation to fill the deadly gap in appropriate HIV medicines
Get our latest news, personal stories, research articles, and job opportunities.